Research finds that there could be hope for new dementia treatment, Crenezumab – Alzheimer’s Society comments
Doug Brown, Chief Policy and Research Officer
| Alzheimer’s Society
Research presented at Alzheimer’s Association International Conference (AAIC) today shows that a study of the immunotherapy treatment Crenezumab has found it can reduce levels of the protein amyloid, associated with dementia.
Crenezumab is designed to fight the toxic proteins in the brain that are associated with Alzheimer’s, but this study doesn’t tell us whether it’s actually able to treat the disease or not.
Researchers found the drug reduced levels of these toxic proteins in the fluid around the brain and spinal cord, but we don’t know if it would have the same effect in the brain itself.
What we need now, is evidence to show if this drug could affectively treat the disease and have a positive effect in people. 1 million people in the UK will have dementia by the time this trial concludes in 2021, and there hasn’t been a new drug to help them for decades, so we’re eagerly awaiting the final results of this research.
